Trial · NCT07502872
TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma
NCT07502872, Phase 2, Not yet recruiting, Brown University
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma. Trials, record NCT07502872. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07502872
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma
- NCT number
- NCT07502872
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 30 participants, estimated
- Lead sponsor
- Brown University
- Conditions
- Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Lymphoma, Lymphoma, B-Cell
- Interventions
- Tafasitamab, Polatuzumab vedotin, Glofitamab, Obinutuzumab
- First posted
- 2026-03-31
- Last updated
- 2026-09-01
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Complete response rate | 3 months after starting therapy | • Complete response (CR) rate after 4 cycles of TPG therapy, evaluated by PET-CT using Lugano criteria |
| Primary | Rate of toxicities | From the day when informed consent is obtained until 90 days following the last administration of study treatment. | Occurrence and severity of adverse events will be examined throughout the treatment using the Common Terminology Criteria for Adverse Events (CTCAE) v6.0, except cytokine release syndrome (CRS) and immune cell-associated neurotoxicity syndrome (ICANS) will be assessed using the American Society of Transplantation and Cellular Therapy (ASTCT) criteria |
| Secondary | Progression-free survival | PFS will be measured from the day of the registration on study until the end of follow up, for up to 5 years | PFS will be determined according to the guidance from the International Working Group |
| Secondary | Event-free survival | EFS will be measured from the day of the registration on study until the end of follow up, for up to 5 years | EFS will be determined using the following events: disease progression, disease recurrence, a switch from TPG to standard chemotherapy (or alternative therapy), initiation of any new therapy for lymphoma after attaining a CR, or death from any cause. |
| Secondary | Overall survival | OS will be measured from the day of the registration on study until the end of follow up, for up to 5 years | OS will be determined using death from any cause and measured from registration until the end of follow up. |
| Secondary | Duration of response | Duration of response will be measured from the day of the first response recored on study until the end of follow up, for up to 5 years | assessed only for patients who achieve an overall response |
| Secondary | Duration of complete response | Duration of complete response will be measured from the first response assessment showing a complete response until the end of follow up, up to 5 years. | assessed only for patients who achieve a complete response |
| Secondary | Health-related quality of life | At timepoints specified in the protocol: at baseline, after Cycle 4 (cycle length is 21 days), at the end of therapy visit (typically 9 months from the start). | HR-QOL will be measured using FACT-Lym instrument. FACT-Lym has a score range of 0 to 88 and the higher scores indicate worse HR-QOL |
| Secondary | Patient-centered measure of treatment burden | At timepoints specified in the protocol: at baseline, after Cycle 4 (cycle length is 21 days), at the end of therapy visit (typically 9 months from the start of therapy). | Measured using the PRIMIS-APSRA instrument. The instrument has a score range 8 to 40 and higher scores indicate better functional status. |
| Secondary | Minimal residual disease | At timepoints specified in the protocol: at baseline, after Cycle 4 (cycle length is 21 days), at the end of therapy (typically 9 months from the start), then every 6 months until 2 years of follow up. | using a ctDNA assay performed at protocol-specified timepoints |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07502872
GET https://conductscience.org/api/trials/v1/NCT07502872/registered